GILD Stock Analysis — Gilead Sciences
Sector: Healthcare
AI Verdict
You're paying a premium for stability in Gilead's drug portfolio, but with earnings set to shrink by -21.2%, the current multiple looks expensive unless new therapies deliver upside.
Competitive Moat
Gilead Sciences owns a portfolio of patent-protected antiviral drugs, including market-defining treatments for HIV and hepatitis C. Its moat comes from intellectual property and clinical expertise in infectious diseases, which create high barriers for generic competition.
Summary
Gilead's stock is drawing attention as its forward P/E has jumped to 25.3x despite analysts expecting a -21.2% drop in earnings next year.
Where It Stands
Gilead delivered a 14.98% one-year return and trades at 25.3x forward earnings—well above the healthcare sector median of 22x—while its RSI of 66.9 signals elevated pullback risk.
Key Metrics
- RSI: 66.9 — Near Overbought
- Trailing P/E: 20.0x
- Forward P/E: 25.3x
- Earnings Growth: -0.2%
- Revenue Growth: +0.1%
- Market Cap: $171.3B
- Dividend Yield: 0.02%
- 1-Year Return: 14.98%
- 52-Week High: $157.29
- 52-Week Low: $108.46
Analyst Consensus
30 Buy · 7 Hold · 0 Sell (37 analysts)
Bull Case
The trailing P/E of 20.0x is below the sector median, suggesting the market still values Gilead's established drug franchises and 5.5% revenue growth.
Bear Case
If the forward P/E of 25.3x compresses to the sector median of 22x amid -21.2% expected EPS decline, shares could see a double-digit percentage drop.
Catalyst to Watch
Watch for clinical trial results or regulatory decisions on pipeline drugs, as positive surprises could offset the expected earnings contraction.